Marcos Lopez Hoyos Scientific director of IDIVAL, President of the Spanish Immunology Association (SEI) ղեկավար Head of Immunology at Marqués de Valdecilla University Hospital, visited GM to analyze the reality of accurate or personalized medicine in Spain. The expert assessed the amount of resources needed for this new paradigm, as well as the projects being implemented in Cantabria.
Ask. Accurate medicine is a new standard in Spain in the short term. What time is it? What does SNS need to keep moving forward?
Answer: We have seen it in the case of COVID-19. we have to invest technical և human resources, we still have very limited resources. The country is advancing the concept of personalized medicine in this area. It is a paradigm shift in medicine. We are no longer going to look at groups of diseases, treat them equally, we must advance the diagnosis of a patient who has a pathology that may be different from other patients, which also changes over time. We have to adapt and be practical.
In our country, it has advanced a lot with cancer, but it is not only with this, but it is applicable in case of any other disease, inflammatory, respiratory, autoimmune, etc. Accurate medicine is based on the use of biomarkers, և many times what is used now are genetic և pathological biomarkers in terms of tissue study, but they are not the only ones. there are many others.
That exact medicine is in the newborn period. We must continue to move forward, as it ական essential և will be necessary to be able to apply the many therapies or treatments that are to come և that will revolutionize the field.
H. According to SEOM, its implementation is still an issue at the national level, how do you assess it? How much has it transformed your daily life into a center?
– We have a big problem, accurate medicine is still attributed to clinical trials. This is an activity that is performed in all hospitals, but is not regulated. The use of precision medicine in the healthcare environment requires huge investments. We are talking about modern biomarkers, which require very sophisticated technology – a very high level of “know-how” from the people who follow, interpret and study them. That’s why this is a very important challenge that needs to be addressed in the SNS.
In addition, accurate medicine requires specialists in other fields to provide relevant data interpretation, knowledge, and exploitation. This drug has been particularly influential in the field of rare diseases ռ oncology, where mass sequencing techniques և cellular markers are used for certain treatments.
“Exact medicine is still attached to clinical trials, it is done in all hospitals, but it is not regulated”
H. One of the most important claims in precision medicine is the inclusion of biomarkers in the SNS portfolio. How can clinical practice be helpful?
We need to start using the specialized resources of this precise medicine to use it in the vital processes that have the greatest impact on health և disease և to better optimize resources on a daily basis. This will allow us to make significant improvements, for example, in getting rid of cancer. For example, in the pathology of pregnancy, it is a pathology that generates a lot of resources, which causes a lot of problems for couples, for people at a very important moment in life, զբաղ practicing accurate medicine in this field can be of great interest. You can use resources to: optimize them in other situations when you probably do not care how much you use them.
H. Do you have a program or initiative in your hospital that proves the value of using biomarkers in this area?
The main project with which we will learn a lot at Valdecilla is Cohorte Cantabria. It is a promising “multidisciplinary group that includes the population of Cantabria at an age when many health events occur between the ages of 40-70”. We are recruiting a significant number of people, we want to reach 50 thousand. With healthy, sick people, we will be able to learn from what happens in these situations, apply many of these biomarkers, and use the ohmic techniques that will generate huge amounts of data. We want to link this to data we already have from people who have given us their permission.
In accurate medicine, we need to start using medical data, but also socio-economic data, which is essential. We want to advance in the science of data so that we can gather information and draw conclusions. In addition, through these individualized studies, we can greatly improve the health of our population. The basic concept is that we do not want to treat groups of pathologies, but each patient with his own specific problem.
“We do not want to treat the groups of pathologies, but each patient with his specific problem.”
P. Cantabria և Valdecilla are committed to a whole infrastructure for the development of this personalized drug. On which lines does it rotate?
In addition to Cohorte Cantabria, we promote clinical trials. The Valdecilla unit has worked on early-stage experiments in which it has learned a great deal from all of this. With this unit, we can start developing new treatments. Soon all those who are implanted should be accompanied by personalized medical projects, as they should be associated with biomarkers. Treatment should be based on the markers on this item. conditions.
At the same time, we have launched the Accurate Medicine Forum, a series of online courses covering all specialties led by Valdecilla-IDIVAL researchers. We are going to set them for 2022, and for 2023 we already have proposals to advance the projects of accurate medicine, bringing the best specialists from the country and abroad.